The present invention features systems and methods for preventing amyloid plaque development by treating plaque precursors to arrest or reverse binding of the plaque forming elements. Proteins, protein binding precursors, fragments, other bioactives or biosimilars are inserted to arrest plaque precipitation and aggregation. Hereditary cystatin C Amyloid Angiopathy (HCCAA) is a disease characterized by early and prolific plaque formation whose effective management is analogous to that of other more common amyloidosis. The cystatin C protein that serves as the key to HCCAA plaques colocalizes, coprecipitates and coglommerates with proteins found in other plaques such as those in Alzheimer's disease. The systems, including chemical and biochemical interventions, useful for treating HCCAA are applicable to slowing, preventing and even reversing these amyloids.